Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

home / precision-medicine-perspectives / real-world-safety-and-efficacy-of-teclistamab-for-patients-with-heavily-pretreated-relapsed

Expert Danai Dima, MD, reviews results of a retrospective, real-world study of teclistamab in patients with R/R MM who would have been considered ineligible for the MajesTEC-1 trial.

EP. 1: Overview of Teclistamab and its MOA in R/R MM

Danai Dima, MD

December 22nd 2023

A description and overview of teclistamab and its mechanism of action.

EP. 2: Patient Characteristics in Real-World Study on Teclistamab

Danai Dima, MD

December 22nd 2023

Danai Dima, MD, further explores the patient characteristics in the R/R MM teclistamab real-world study.

EP. 3: The Real-World Effectiveness of Treatment with Teclistamab for Patients with R/R MM

Danai Dima, MD

December 22nd 2023

Discussion of the real-world effectiveness of teclistamab in R/R MM and the impact on treatment guidelines and practice.

EP. 4: The Efficacy and Safety data and the Potential Impact on Treatment Guidelines and Practice

Danai Dima, MD

December 22nd 2023

Presenting real-world data on the efficacy and safety of teclistamab for R/R MM.

EP. 5: How Do These Data Apply to Community Oncologists?

Danai Dima, MD

December 22nd 2023

Explanation of how these data apply to community oncologists.